OtherClinical Investigations (Human)
68Ga-DOTATATE PET/CT interobserver agreement for neuroendocrine tumor assessments: results from a prospective study on 50 patients
Wolfgang Peter Fendler, Martin Barrio, Claudio Spick, Martin Allen-Auerbach, Valentina Ambrosini, Matthias Benz, Christina Bluemel, Ravinder Grewal, Constantin Lapa, Matthias Miederer, Guillaume Nicolas, Tibor Schuster, Johannes Czernin and Ken Herrmann
Journal of Nuclear Medicine August 2016, jnumed.116.179192; DOI: https://doi.org/10.2967/jnumed.116.179192
Wolfgang Peter Fendler
1 Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA;
Martin Barrio
1 Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA;
Claudio Spick
1 Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA;
Martin Allen-Auerbach
1 Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA;
Valentina Ambrosini
2 Nuclear Medicine, Department of Experimental Diagnostic and Specialized Medicine;
Matthias Benz
3 Clinic of Radiology and Nuclear Medicine, University of Basel Hospital, Basel, Switzerland;
Christina Bluemel
4 Dept of Nuclear Medicine, Julius-Maximilians-University of Würzburg, Würzburg, Germany;
Ravinder Grewal
5 Molecular Imaging and Therapy Service, Department of Radiology;
Constantin Lapa
4 Dept of Nuclear Medicine, Julius-Maximilians-University of Würzburg, Würzburg, Germany;
Matthias Miederer
6 Department of Nuclear Medicine, University Medical Center Mainz, Mainz, Germany;
Guillaume Nicolas
3 Clinic of Radiology and Nuclear Medicine, University of Basel Hospital, Basel, Switzerland;
Tibor Schuster
7 Department of Family Medicine, McGill University, Montreal, Quebec, Canada;
Johannes Czernin
1 Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA;
Ken Herrmann
8 Universitätsklinikum Würzburg, United States
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
68Ga-DOTATATE PET/CT interobserver agreement for neuroendocrine tumor assessments: results from a prospective study on 50 patients
Wolfgang Peter Fendler, Martin Barrio, Claudio Spick, Martin Allen-Auerbach, Valentina Ambrosini, Matthias Benz, Christina Bluemel, Ravinder Grewal, Constantin Lapa, Matthias Miederer, Guillaume Nicolas, Tibor Schuster, Johannes Czernin, Ken Herrmann
Journal of Nuclear Medicine Aug 2016, jnumed.116.179192; DOI: 10.2967/jnumed.116.179192
68Ga-DOTATATE PET/CT interobserver agreement for neuroendocrine tumor assessments: results from a prospective study on 50 patients
Wolfgang Peter Fendler, Martin Barrio, Claudio Spick, Martin Allen-Auerbach, Valentina Ambrosini, Matthias Benz, Christina Bluemel, Ravinder Grewal, Constantin Lapa, Matthias Miederer, Guillaume Nicolas, Tibor Schuster, Johannes Czernin, Ken Herrmann
Journal of Nuclear Medicine Aug 2016, jnumed.116.179192; DOI: 10.2967/jnumed.116.179192
Jump to section
Related Articles
Cited By...
- 68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study
- High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT
- 111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden
- Current Concepts in 68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies
- Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented
- 68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study
- Somatostatin Receptor 2-Targeting Compounds